Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China - 2Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
- 3Ancient fire discovery marks significant milestone in human history
- 4Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- 5Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- Artemis II astronauts make long-distance call to the space station as they head home from the moon
- Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- Middle East hotels hit pandemic-era lows amid Iran war
- Make your choice for a definitive Christmas place to get-away!
- 6 Top Computer game Control center
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- 2 ways you can conserve the water used to make your food
- Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
